Enliven Therapeutics (ELVN) Cash from Operations Growth (3y) (2022 - 2026)
Enliven Therapeutics (ELVN) Cash from Operations Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 34.32% |
| 10 | Enliven Therapeutics | 3.43 Bn | 2.98 Bn | - | 2.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.55% |
| Dec 31, 2025 | -24.82% |
| Sep 30, 2025 | -27.23% |
| Jun 30, 2025 | -33.78% |
| Mar 31, 2025 | -32.55% |
| Dec 31, 2024 | -11.28% |
| Sep 30, 2024 | -3.80% |
| Jun 30, 2024 | -25.39% |
| Mar 31, 2024 | -21.51% |
| Dec 31, 2023 | -14.71% |
| Sep 30, 2023 | -15.39% |
| Jun 30, 2023 | -9.19% |
| Mar 31, 2023 | -29.82% |
| Dec 31, 2022 | -0.43% |
| Sep 30, 2022 | -0.88% |
| Jun 30, 2022 | -11.44% |
| Mar 31, 2022 | -62.67% |